ARTSaVIT

Cancer Apoptosis Technology

Health Tech & Life Sciences
Non Active, Jun 2018 ceased to operate
Follow

Company Overview

Snapshot

Founded in February 2014 by Sarit Larisch, ARTSaVIT operated with 1–10 employees. The company raised a total of $6.3M across 2 funding rounds from 5 investors. In January 2017, ARTSaVIT secured funding from Carmel-Haifa University Economic Corporation, Carmel Innovation Fund, Arkin Bio, Pontifax, and M Ventures.

Business overview

ARTSaVIT is a Health Tech & Life Sciences company focused on developing a molecular mechanism of apoptosis induced by apoptotic-related tumor suppressors (ARTS). The company's core technology involves determining how the binding of ARTS to inhibitors of apoptosis proteins and other apoptotic regulators causes caspase activation and cell death. ARTSaVIT's research aims to identify and screen small-molecule ARTS mimetics that can selectively kill cancer cells, serving as anticancer drugs within the pharmaceuticals, oncology, and biotechnology sectors.

Strategic signal

In January 2017, ARTSaVIT raised $6.3 million, a significant capital injection that validated its innovative approach to cancer treatment. This funding round, involving multiple investors, underscored confidence in the company's research into apoptosis-related tumor suppressors and its potential to develop novel anticancer drugs. The investment signaled strong market interest in early-stage biotechnology companies addressing critical unmet needs in oncology.

Log in to access full profile

Company Intelligence Q&A

What is ARTSaVIT's primary focus?
ARTSaVIT focuses on developing a molecular mechanism of apoptosis induced by apoptotic-related tumor suppressors (ARTS) to identify small-molecule ARTS mimetics for anticancer drugs.
When was ARTSaVIT founded?
ARTSaVIT was founded in February 2014.
Who founded ARTSaVIT?
Sarit Larisch founded ARTSaVIT.
What was a key funding event for ARTSaVIT?
In January 2017, ARTSaVIT raised $6.3 million from Carmel-Haifa University Economic Corporation, Carmel Innovation Fund, Arkin Bio, Pontifax, and M Ventures.
What is the current status of ARTSaVIT?
ARTSaVIT is Non Active and ceased to operate in June 2018.
Log in to access full profile